Banjoko S, Akinlade K
Indian J Clin Biochem. 2011; 25(3):289-94.
PMID: 21731200
PMC: 3001839.
DOI: 10.1007/s12291-010-0055-5.
Ladero J, Enriquez de Salamanca R, Chinarro S
Arch Dermatol Res. 1981; 270(2):171-3.
PMID: 7247454
DOI: 10.1007/BF00408229.
Shenfield G, McCann V, Tjokresetio R
Diabetologia. 1982; 22(6):441-4.
PMID: 7106444
DOI: 10.1007/BF00282587.
Boulton A, Worth R, Drury J, Hardisty C, Wolf E, Cudworth A
Diabetologia. 1984; 26(1):15-9.
PMID: 6706042
DOI: 10.1007/BF00252256.
Barbosa J, Saner B
Diabetologia. 1984; 27(5):487-92.
PMID: 6439587
DOI: 10.1007/BF00290381.
Association studies between Type 1 (insulin-dependent) diabetes and 27 genetic markers: lack of association between Type 1 diabetes and Kidd blood group.
Hodge S, Anderson C, Neiswanger K, Rubin R, Sparkes R, Sparkes M
Diabetologia. 1983; 25(4):343-7.
PMID: 6416912
DOI: 10.1007/BF00253199.
Survey of the human acetylator polymorphism in spontaneous disorders.
Evans D
J Med Genet. 1984; 21(4):243-53.
PMID: 6387123
PMC: 1049291.
DOI: 10.1136/jmg.21.4.243.
The acetylator phenotypes of Saudi Arabian diabetics.
Evans D, Paterson S, FRANCISCO P, Alvarez G
J Med Genet. 1985; 22(6):479-83.
PMID: 4078878
PMC: 1049509.
DOI: 10.1136/jmg.22.6.479.
The effect of glucose on acetylation status.
Suhardjono D, Boutagy J, Shenfield G
Br J Clin Pharmacol. 1986; 22(4):401-8.
PMID: 3768255
PMC: 1401158.
DOI: 10.1111/j.1365-2125.1986.tb02909.x.
Genetic and metabolic risk factors for the development of late complications in type I (insulin-dependent) diabetes.
Pontiroli A, Calderara A, Bonisolli L, Maffi P, De Pasqua A, Margonato A
Acta Diabetol Lat. 1986; 23(4):351-66.
PMID: 3471027
DOI: 10.1007/BF02582069.
Acetylator phenotypes in diabetes mellitus.
MALCZEWSKI B, Kopec A, Rowinska-Marcinska K
Acta Diabetol Lat. 1988; 25(1):41-8.
PMID: 3407376
DOI: 10.1007/BF02581244.
Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.
OConnor P, Feely J
Clin Pharmacokinet. 1987; 13(6):345-64.
PMID: 3325214
DOI: 10.2165/00003088-198713060-00001.
Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Clark D
Drugs. 1985; 29(4):342-75.
PMID: 2859977
DOI: 10.2165/00003495-198529040-00003.
N-acetylation in healthy and diseased children.
Hadasova E, Brysova V, KADLCAKOVA E
Eur J Clin Pharmacol. 1990; 39(1):43-7.
PMID: 2276387
DOI: 10.1007/BF02657055.
The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans.
Gwilt P, Nahhas R, Tracewell W
Clin Pharmacokinet. 1991; 20(6):477-90.
PMID: 2044331
DOI: 10.2165/00003088-199120060-00004.
N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark.
Lower Jr G, Nilsson T, Nelson C, Wolf H, Gamsky T, Bryan G
Environ Health Perspect. 1979; 29:71-9.
PMID: 510245
PMC: 1637362.
DOI: 10.1289/ehp.792971.
Diabetic dimorphism according to acetylator status.
Burrows A, Hockaday T, Mann J, Taylor J
Br Med J. 1978; 1(6107):208-10.
PMID: 340001
PMC: 1602542.
DOI: 10.1136/bmj.1.6107.208.